214 related articles for article (PubMed ID: 17542746)
1. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
Flowers CR
Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
[TBL] [Abstract][Full Text] [Related]
2. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
[TBL] [Abstract][Full Text] [Related]
5. Idiotype vaccine strategies for treatment of follicular lymphoma.
Mahaseth H; Brody JD; Sinha R; Shenoy PJ; Flowers CR
Future Oncol; 2011 Jan; 7(1):111-22. PubMed ID: 21174542
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
8. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.
Lee ST; Jiang YF; Park KU; Woo AF; Neelapu SS
Expert Opin Biol Ther; 2007 Jan; 7(1):113-22. PubMed ID: 17150023
[TBL] [Abstract][Full Text] [Related]
9. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Levy R; Ganjoo KN; Leonard JP; Vose JM; Flinn IW; Ambinder RF; Connors JM; Berinstein NL; Belch AR; Bartlett NL; Nichols C; Emmanouilides CE; Timmerman JM; Gregory SA; Link BK; Inwards DJ; Freedman AS; Matous JV; Robertson MJ; Kunkel LA; Ingolia DE; Gentles AJ; Liu CL; Tibshirani R; Alizadeh AA; Denney DW
J Clin Oncol; 2014 Jun; 32(17):1797-803. PubMed ID: 24799467
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966
[No Abstract] [Full Text] [Related]
11. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
[TBL] [Abstract][Full Text] [Related]
12. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
Bendandi M; Gocke CD; Kobrin CB; Benko FA; Sternas LA; Pennington R; Watson TM; Reynolds CW; Gause BL; Duffey PL; Jaffe ES; Creekmore SP; Longo DL; Kwak LW
Nat Med; 1999 Oct; 5(10):1171-7. PubMed ID: 10502821
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
[TBL] [Abstract][Full Text] [Related]
14. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
Reinis M
Curr Opin Mol Ther; 2007 Jun; 9(3):291-8. PubMed ID: 17608028
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
[TBL] [Abstract][Full Text] [Related]
16. Cancer vaccine strategies get bigger and better.
de Gruijl TD; Curiel DT
Nat Med; 1999 Oct; 5(10):1124-5. PubMed ID: 10502808
[No Abstract] [Full Text] [Related]
17. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
Reinis M
Curr Opin Mol Ther; 2008 Oct; 10(5):526-34. PubMed ID: 18830928
[TBL] [Abstract][Full Text] [Related]
18. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
Freedman A; Neelapu SS; Nichols C; Robertson MJ; Djulbegovic B; Winter JN; Bender JF; Gold DP; Ghalie RG; Stewart ME; Esquibel V; Hamlin P
J Clin Oncol; 2009 Jun; 27(18):3036-43. PubMed ID: 19414675
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM; McGaughey DS; Jaffe ES; Chong EA; Reynolds CW; Berry DA; Santos CF; Popa MA; McCord AM; Kwak LW
J Clin Oncol; 2011 Jul; 29(20):2787-94. PubMed ID: 21632504
[TBL] [Abstract][Full Text] [Related]
20. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
Hurvitz SA; Timmerman JM
Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]